Array Biopharma (ARRY) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.33 +14.87%
Revenue Growth %: -18.0%
Financial Fact:
Net loss: -28.61M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: -18.0%
Financial Fact:
Net loss: -28.61M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $10.29 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Grand Canyon Education (LOPE) Tops Q3 EPS by 1c
- Deluxe Corp. (DLX) Tops Q3 EPS by 11c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
